1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
64DB080E566C8212F85257F7F0072812B
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-disease-awareness-program-excellence-interview-narratives-best-practices?opendocument
18
19opendocument
2018.212.83.37
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Marketing Management Marketing Strategy

Disease Awareness Program Excellence: Interview Narratives and Best Practices

ID: 5409


Features:

15 Info Graphics

4 Data Graphics

25 Metrics

12 Narratives


Pages/Slides: 26


Published: 2016


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Disease Awareness Program Excellence: Interview Narratives and Best Practices"

STUDY OVERVIEW

Disease state awareness campaigns have long been used by the pharmaceutical industry to disseminate unbranded information to key external stakeholders, such as physicians and patients. These programs also set the table for future marketing efforts at product launch and post-launch. Today, more than ever, understanding how to utilize these programs is critical.

Best Practices, LLC conducted a primary research study that looked at issues such as when are companies first using disease awareness programs and when should you invest the most resources in disease awareness campaigns?

The study provides highlights from interviews, spotlighting effective practices and challenges participants have faced regarding disease awareness programs. In addition, this document presents best practices and pitfalls that participants have learned from past disease awareness campaigns.


KEY TOPICS

  • Narratives from Interviews
  • Best Practices and Pitfalls
KEY NARRATIVE TOPICS
  • Disease Awareness to Prepare For Launch
  • Utilizing Clinical Trial Results for Disease Awareness
  • European Regulatory Approaches
  • Finding Success in Crowded Therapeutic Areas
  • Developing Relationships with Patient Advocacy Groups
  • Conference Benefits


SAMPLE KEY FINDINGS

  • Most Impactful Awareness Activities are Personal Interactions with Physicians/TLs: Interviewed disease awareness veterans spoke of the importance of personal interactions with prescribers and thought leaders. "Without a doubt, what our development and medical colleagues are able to do in a conference setting is so credible," said one senior director.


METHODOLOGY
  • Sixteen leaders at 16 leading pharmaceutical and biotech organizations participated in this study. In addition, one global communications firm representing a biopharma client also participated.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Public Relations; Health Care; Biopharmaceutical


Companies Profiled:
Bayer; Abbvie; Genzyme; Adamas Pharmaceuticals; AstraZeneca; Biogen; Novartis; Eli Lilly; FleishmanHillard; Fresenius Medical Care AG & Co. KGaA; ZS Pharma; Indivior; Merck; Catalyst Pharmaceuticals; Prometheus Therapeutics & Diagnostics; Tokai Pharmaceuticals; Vertex Pharmaceuticals


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.